Microbiome-Mediated Effects of Cannabis and CBD on Neurotransmitter-Related Molecular Networks and Anxiety
Nichole Reisdorph, PhD
Professor Mass Spectrometry Facility Director, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
Microbiome-Mediated Effects of Cannabis and CBD on Neurotransmitter-Related Molecular Networks and Anxiety
Orally consumed Cannabis and extracted cannabidiol (CBD) products are becoming widely used supplements for a range of health disorders, including depression and anxiety. However, there is limited understanding regarding how Cannabis and CBD affect those living with these and other psychiatric conditions. Personal reports and some early research studies suggest that the effects of orally consumed tetrahydrocannabinol (THC), CBD, and Cannabis are largely dependent on the individual. We hypothesize that some of this variability in a person’s response is due to differences in an individual’s gut microbiome composition. Therefore, our research will help determine if an individual’s gut microbiome plays a role in how he/she/they metabolize CBD, THC, and other Cannabis molecules when orally ingested. In addition, our research will help understand the effects of CBD and Cannabis on anxiety and depression by measuring important neurotransmitters known to be related to anxiety/depression. These include dopamine, serotonin, kynurenine, epinephrine, and several endocannabinoids. Results can be used to develop similar studies that focus on other conditions such as post-traumatic stress disorder (PTSD) and to determine if ingestion of a pro- or pre-biotic can influence an individual’s response to CBD or Cannabis.